| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2008, p. 2977-2979, Vol. 52, No. 8
0066-4804/08/$08.00+0 doi:10.1128/AAC.00175-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

MICOER-Institute, Munich, Germany,1 Medical Institute, Ministry of the Interior, Sofia, Bulgaria,2 Medizinisches Versorgungszentrum Labor Dr. Tiller and Partner, Munich, Germany,3 Department of Microbiology, Medical University, Sofia, Bulgaria,4 Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey5
Received 7 February 2008/ Returned for modification 27 March 2008/ Accepted 28 May 2008
Two Pseudomonas aeruginosa urine isolates from Bulgaria and Germany produced two new VIM-2 variants. VIM-15 had one amino acid substitution (Tyr218Phe) which caused a significant increase in hydrolytic efficiency. The substitution Ser54Leu, characterizing VIM-16, showed no influence on enzyme activity. Both genes were part of class I integrons located in the chromosome.
Published ahead of print on 2 June 2008.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |